Publications by authors named "Federico FeLizzi"

Claim this Profile
Q
Qualitative Exploration of the Visual Function Impairments and Health-Related Quality of Life Impacts of Amblyopia in Adult and Pediatric Populations.
Sharan Randhawa, Natasha Griffiths, Paul O'Brien, Charlotte Panter, Kieran Boparai, Federico Felizzi

Ophthalmol Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis.
Shelby Sydnor, Swarnendu Chatterjee, Philip Cooney, Simarjeet Kaur, Tom Macmillan, Federico Felizzi

Diabetes Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Amblyopia Quality of Life (AmbQoL): Development and Content Validation of a Novel Health-Related Quality of Life Instrument for Use in Adult and Pediatric Amblyopia Populations.
Ann Webber, Sharan Randhawa, Federico Felizzi, Mercedesz Soos, Rob Arbuckle

Ophthalmol Ther· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Social Media Listening Study to Understand the Unmet Needs and Quality of Life in Adult and Pediatric Amblyopia Patients.
Annie Syntosi, Federico Felizzi, Christine Bouchet

Ophthalmol Ther· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine Learning Methods in Health Economics and Outcomes Research-The PALISADE Checklist: A Good Practices Report of an ISPOR Task Force.
William V Padula, Noemi Kreif, David J Vanness, Blythe Adamson, Juan-David Rueda, Federico Felizzi

Value Health· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mixture Cure Models in Oncology: A Tutorial and Practical Guidance.
Federico Felizzi, Noman Paracha, Johannes Pöhlmann, Joshua Ray

Pharmacoecon Open· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Scott J Spencer, Gregory F Guzauskas, Federico FeLizzi, Aino Launonen, Keith Dawson

J Manag Care Spec Pharm· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semiparametric estimation of the cure fraction in population-based cancer survival analysis.
Ennan Gu, Jiajia Zhang, Wenbin Lu, Lianming Wang, Federico Felizzi

Stat Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
Keith A Betts, Per-Olof Thuresson, Federico Felizzi, Ella X Du, Ibou Dieye

J Comp Eff Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Sivignon Marine, Roze Stéphane, Plommet Nicolas, Federico Felizzi, Noman Paracha

J Med Econ· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Umang Ondhia, H J Conter, Scott Owen, Anna Zhou, Julian Nam, Federico Felizzi

J Med Econ· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer.
Rodolfo Bordoni, Fortunato Ciardiello, Joachim von Pawel, Diego Cortinovis, Thomas Karagiannis, Federico Felizzi

Clin Lung Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
Louis Fehrenbacher, Joachim von Pawel, Keunchil Park, Achim Rittmeyer, David R Gandara, Federico Felizzi

J Thorac Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyzing and constraining signaling networks: parameter estimation for the user.
Florian Geier, Georgios Fengos, Federico Felizzi, Dagmar Iber

Methods Mol Biol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced cellular sensitivity from partitioning the integrin receptors into multiple clusters.
Federico Felizzi, Dagmar Iber

Phys Rev E Stat Nonlin Soft Matter Phys· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network-of-queues approach to B-cell-receptor affinity discrimination.
Federico Felizzi, Federico Comoglio

Phys Rev E Stat Nonlin Soft Matter Phys· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons.
João R Gomes, João T Costa, Carlos V Melo, Federico Felizzi, Patrícia Monteiro

J Neurosci· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis